Сопутствующее закрытие аппендикса левого предсердия и абляция импульсным полем - Азия (OPTION-A)
Subjects enrolled in the OPTION-A study will be clinically indicated for atrial fibrillation (AF) ablation procedure with the FARAPULSE™ PFA system and treatment with WATCHMAN LAAC Device, per physician's medical judgement and according to hospitals' standard of care during the same procedure.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
The OPTION-A Study is an observational, prospective, single-arm, multi-center non-mandated post-market study. Subjects enrolled in the OPTION-A study will be clinically indicated for atrial fibrillation (AF) ablation procedure with the FARAPULSE PFA system and treatment with WATCHMAN LAAC Device, per physician's medical judgement and according to hospitals' standard of care. The objective(s) of the OPTION-A Study is to evaluate safety and effectiveness of catheter ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent implant of Left Atrial Appendage closure (LAAC) with the WATCHMAN™ LAA Closure device in a concomitant procedure.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Места учебы
-
-
-
Hong Kong, Гонконг
- Queen Mary Hospital
-
Hong Kong, Гонконг
- Prince of Wales Hospital
-
Hong Kong, Гонконг
- Princess Margaret Hospital
-
Kowloon, Гонконг
- Queen Elizabeth Hospital
-
-
-
-
-
Beijing, Китай
- Xuanwu Hospital Capital Medical University
-
Beijing, Китай
- Beijing Anzhen Hospital of the Capital University of Medical Sciences
-
Chengdu, Китай
- Huaxi Hospital of Sichuan University
-
Chengdu, Китай
- The First Affiliated Hospital of Chengdu Medical College
-
Guangzhou, Китай
- The Third Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Китай
- Guangdong Nanfang Hospital
-
Guiyang, Китай
- The Affiliated Hospital of Guizhou Medical University
-
Hangzhou, Китай
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
-
Jinan, Китай
- QiLu Hospital of ShanDong University
-
Kunming, Китай
- First People's Hospital of Yunnan Province
-
Nantong, Китай
- Affiliated Hospital of Nantong University
-
Taiyuan, Китай
- Shanxi Cardiovascular Hospital
-
Zhuhai, Китай
- Zhuhai People's Hospital
-
Zigong, Китай
- Zigong First People's Hospital
-
-
Jiangsu
-
Suzhou, Jiangsu, Китай
- The First Affiliated Hospital of Soochow University
-
-
-
-
-
Kuala Lumpur, Малайзия
- Institute Jantung Negara
-
Kuching, Малайзия
- Pusat Jantung Sarawak
-
-
-
-
-
Singapore, Сингапур
- Asian Heart and Vascular Centre
-
-
-
-
-
Taichung, Тайвань
- China Medical University Hospital
-
Taichung, Тайвань
- Taichung Veterans General Hospital
-
Taipei, Тайвань
- National Taiwan University Hospital
-
Taipei, Тайвань
- Taipei Veterans General Hospital
-
-
-
-
-
Fukuoka-ken, Япония
- Kokura Memorial Hospital
-
Kanagawa, Япония
- Yokosuka Kyosai Hospital
-
Kawasaki, Япония
- Kawasaki Saiwai Hospital
-
Meguro-ku, Япония
- Toho University Ohashi Medical Center
-
Osaka, Япония
- Osaka Keisatsu Hospital
-
Yokohama, Япония
- Yokohama city minato Red Cross Hospital
-
-
Kanagawa
-
Kamakura-shi, Kanagawa, Япония
- Shonan Kamakura General Hospital
-
-
Miyagi
-
Sendai, Miyagi, Япония
- Sendai Kousei Hospital
-
-
Okayama Kurashiki-shi
-
Kurashiki-shi, Okayama Kurashiki-shi, Япония
- Kurashiki Central Hospital
-
-
Saitama
-
Saitama, Saitama, Япония
- Saitama Red Cross Hospital
-
-
Tokyo
-
Fuchu-shi, Tokyo, Япония
- Sakakibara Heart Institute, Sakakibara Heart Foundation
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Subjects enrolled in the OPTION-A study will be clinically indicated for an Atrial Fibrillation ablation procedure utilizing the FARAPULSE PFA System as well as implantation of the WATCHMAN device per physician's medical judgement, and according to the hospitals' standard of care during the same procedure. The subjects selected for participation in the study will be from the investigator's general patient population. The investigator or designee has the responsibility for screening all potential subjects and selecting those who meet study eligibility criteria.
Описание
Inclusion Criteria:
- Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN for LAAC, per physician medical judgement and as per hospitals' standard of care.
- Subjects who are willing and able to provide informed consent.
- Subjects who are willing and able to participate in all testing associated with this clinical study at an approved clinical investigational center.
- Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.
Exclusion Criteria:
- Subjects who underwent prior AF ablation procedure.
- Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
- Already surgically closed or otherwise excluded LAA.
- The LAA anatomy does not accommodate a Closure Device.
- Known or suspected atrial myxoma.
- Presence of intracardiac thrombus.
- Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an ASD/PFO device.
- Subjects with a presence of a mechanical valve prosthesis in any position.
- Subjects with a myocardial infarction within 30 days prior to enrollment.
- Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 90 days prior to enrollment.
- Any planned electrical cardioversion within 30 days following LAAC device implant.
- Subjects with a known inability to obtain vascular access.
- Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy), active conditions (e.g. infection, bleeding disorder, unstable angina) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present*.
- Subjects with any active conditions (e.g. infection, bleeding disorder, unstable angina) are present.
- Subjects with any contraindications to short term use of anticoagulation therapy, or aspirin for conditions different from atrial fibrillation.
- Subjects who are pregnant or planning to be pregnant.
- Subjects with a life expectancy of ≤ 1 year per investigator's opinion.
- Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Treatment Subjects
A subject is considered enrolled once an approved informed consent form has been signed and dated. Enrolled Subjects will undergo AF ablation procedure with the FARAPULSE PFA System, followed by WATCHMAN implant during the same procedure. |
The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath. The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Periprocedural or procedure-related Composite Serious Adverse Events will be assessed
Временное ограничение: 30 days post index procedure
|
The primary safety endpoint (PSE) is the proportion of subjects with one or more of the periprocedural device or procedure-related Composite Serious Adverse Events (CSAEs) assessed at 30 days following the Index Procedure. |
30 days post index procedure
|
|
Acute Treatment Success will be assessed
Временное ограничение: between index procedure and 30 days post index procedure
|
The primary effectiveness endpoint (PEE) is the proportion of subjects with Acute Treatment Success assessed among those receiving ≥1 PFA application and who have a WATCHMAN attempted or implanted. |
between index procedure and 30 days post index procedure
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Device or procedure-related Composite Serious Adverse Events (CSAEs) assessed
Временное ограничение: 1 year post index procedure
|
Device or procedure-related Composite Serious Adverse Events (CSAEs) assessed at 360 days following the Index Procedure |
1 year post index procedure
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- PF316
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .